BiotechTube

Gardasil-9

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Papillomavirus Vaccines

Conditions

Papillomavirus Vaccines

Trial Timeline

Apr 6, 2018 → Dec 30, 2023

NCT ID
NCT03350698

About Gardasil-9

Gardasil-9 is a approved stage product being developed by Merck for Papillomavirus Vaccines. The current trial status is unknown. This product is registered under clinical trial identifier NCT03350698. Target conditions include Papillomavirus Vaccines.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03350698ApprovedUNKNOWN

Competing Products

20 competing products in Papillomavirus Vaccines

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
25
9vHPV vaccineMerckPhase 3
77
Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
85
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
77
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
77
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administrationMerckPre-clinical
23
GardasilMerckApproved
85
GardasilMerckPhase 2
52
9vHPV VaccineMerckPhase 3
77
9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3
77
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant VaccineMerckPhase 3
77
V503 + GARDASILMerckPhase 3
77
9vHPV VaccineMerckPhase 3
77
Gardasil vaccineMerckPre-clinical
23
V503MerckPhase 3
77
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) + PlaceboMerckPhase 3
77
V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)MerckPhase 3
77
9vHPV vaccineMerckPhase 3
77
Gardasil™ + PlaceboMerckPhase 3
77
V503 + GardasilMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85